Published in J Immunol on December 15, 1995
C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med (2001) 4.54
Activation of p38 MAPK is required in monocytic and neuronal cells for HIV glycoprotein 120-induced neurotoxicity. J Immunol (2010) 1.07
Cell surface expression and function of the macromolecular c1 complex on the surface of human monocytes. Front Immunol (2012) 0.91
The triggering receptor expressed on myeloid cells 2 inhibits complement component 1q effector mechanisms and exerts detrimental effects during pneumococcal pneumonia. PLoS Pathog (2014) 0.87
Cbln1 accumulates and colocalizes with Cbln3 and GluRdelta2 at parallel fiber-Purkinje cell synapses in the mouse cerebellum. Eur J Neurosci (2009) 0.83
Monocyte Expressed Macromolecular C1 and C1q Receptors as Molecular Sensors of Danger: Implications in SLE. Front Immunol (2014) 0.82
Phagocytotic competence of differentiated U937 cells for colloidal drug delivery systems in immune cells. Inflammation (2011) 0.76
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol (1978) 1.79
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood (1995) 1.75
Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol (1974) 1.69
Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation (2001) 1.64
Antibody-independent interaction of the first component of complement with Gram-negative bacteria. Infect Immun (1978) 1.60
Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun (1981) 1.43
A 66-kilodalton heat shock protein of Salmonella typhimurium is responsible for binding of the bacterium to intestinal mucus. Infect Immun (1992) 1.41
Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem (1996) 1.35
Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol (2000) 1.25
Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 1.23
[Measurement of complement with a microliter method]. Z Med Mikrobiol Immunol (1969) 1.22
Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum (1988) 1.20
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry (1976) 1.20
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry (1976) 1.20
Interactions between mycoplasma pneumoniae and the first components of complement. Infect Immun (1977) 1.17
Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med (1987) 1.14
Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells. J Immunol (2001) 1.14
PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer (2010) 1.11
Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol (2000) 1.11
Inflammation in areas of remote changes following focal brain lesion. Prog Neurobiol (2005) 1.11
vacA genotypes and genetic diversity in clinical isolates of Helicobacter pylori. Clin Diagn Lab Immunol (1998) 1.10
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry (1976) 1.07
Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera. Immunology (1980) 1.05
Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03
Antibody-independent killing of gram-negative bacteria via the classical pathway of complement. Immunol Lett (1987) 1.03
Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis. J Neurol Sci (1995) 0.99
In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015). Eur J Cancer Clin Oncol (1987) 0.97
Evidence for direct binding of the first component of complement, C1, to outer membrane proteins from Salmonella minnesota. Curr Top Microbiol Immunol (1985) 0.97
Biosynthesis of the collagen-like C1q molecule and its receptor functions for Fc and polyanionic molecules on macrophages. Curr Top Microbiol Immunol (1983) 0.95
Interaction of purified lipoteichoic acid with the classical complement pathway. Infect Immun (1986) 0.94
The role of accessory cells in polyclonal T cell activation. I. Both induction of interleukin 2 production and of interleukin 2 responsiveness by concanavalin A are accessory cell dependent. Eur J Immunol (1983) 0.94
Requirement for an additional serum factor essential for the antibody-independent activation of the classical complement sequence by Gram-negative bacteria. Infect Immun (1982) 0.93
High-throughput phenotyping of avoidance learning in mice discriminates different genotypes and identifies a novel gene. Genes Brain Behav (2012) 0.93
Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains. Genes Brain Behav (2006) 0.92
Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol (1982) 0.92
IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol (2000) 0.91
Activation of the first component of complement evidence for an internal activation step. J Immunol (1972) 0.91
The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes. Prog Allergy (1982) 0.89
The role of the classical pathway for the bactericidal effect of normal sera against gram-negative bacteria. Curr Top Microbiol Immunol (1985) 0.89
Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice. Clin Exp Immunol (1996) 0.89
Ultracentrifugation studies on the native form of the first component of human complement (C1). FEBS Lett (1976) 0.89
The first component of complement in serum: evidence for a hitherto unrecognized factor in C1 necessary for internal activation. J Immunol (1973) 0.88
Clinical and immunological studies in a case of selective complete C1q deficiency. Clin Exp Immunol (1979) 0.88
The functions of endogenous C1q, a subcomponent of the first component of complement, as a receptor on the membrane of macrophages. Mol Immunol (1982) 0.88
Gene expression of the A- and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. J Immunol (1991) 0.88
Expression of membrane C1q in human monocyte-derived macrophages is developmentally regulated and enhanced by interferon-gamma. FEBS Lett (2001) 0.87
Contributions of C1q, bacterial lipopolysaccharide, and porins during attachment and ingestion phases of phagocytosis by murine macrophages. Infect Immun (1986) 0.86
Differentiation of hemolytically active fluid-phase and cell-bound human C1q by an ant venom-derived polysaccharide. J Immunol (1980) 0.86
The Cl inactivator from guinea pig serum. 3. Characterization and kinetic data of the reaction between the inactivator and EACl and EACl4. Immunochemistry (1972) 0.85
Purification and characterization of human, guinea pig and mouse C1q by fast protein liquid chromatography (FPLC). J Immunol Methods (1984) 0.84
Molecular cloning and characterization of the complementary DNA coding for the B-chain of murine Clq. FEBS Lett (1989) 0.84
Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis. Correlation of in situ hybridization and northern blot results with function and protein concentration in synovium and primary cell cultures. Arthritis Rheum (1995) 0.84
MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer (2000) 0.84
Functional domains of the human C1q A-chain. Behring Inst Mitt (1993) 0.83
Immunofluorescence studies on the subcomponents of the first component of complement (C1): detection of C1q and C1s in different cells of biopsy material and on human as well as on guinea pig peritoneal macrophages. Immunobiology (1981) 0.83
Autoreactivity to mouse C1q in a murine model of SLE. Rheumatol Int (1995) 0.83
Mode of interaction of different polyanions with the first (C1,C1) the second (C2) and the fourth (C4) component of complement. IV. Activation of C1 in serum by polyanions. Immunology (1976) 0.83
Electron microscopic study showing antibody-independent binding of C1q, a subcomponent of the first component of complement, to serum-sensitive salmonellae. Infect Immun (1984) 0.83
C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. J Biol Chem (1997) 0.83
Non-sense and missense mutations in the structural genes of complement component C1q A and C chains are linked with two different types of complete selective C1q deficiencies. J Immunol (1995) 0.83
Cognitive impact of cytotoxic agents in mice. Psychopharmacology (Berl) (2014) 0.83
Insoluble polyanions as activators of both pathways of complement. Immunology (1977) 0.83
Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies. J Clin Invest (1989) 0.83
C1q-bearing immune complexes detected by a monoclonal antibody to human C1q in rheumatoid arthritis sera and synovial fluids. Rheumatol Int (1991) 0.82
[In vitro studies on the mode of action and differences to heparin. Anticomplementary effect of a semisynthetic pentosan-polysulfo-ester]. Z Naturforsch B (1971) 0.82
Complement component deficiencies and infection: C5, C8 and C3 deficiencies in three families. Eur J Pediatr (1992) 0.82
Inactivation of complement by L-asparaginase preparations not correlated with enzyme content. Nat New Biol (1972) 0.82
The reconstitution of human C1, the first complement component: binding of C1r and C1s to C1q influences the C1q conformation. FEBS Lett (1981) 0.82
Complement component C1 and the collectins: parallels between routes of acquired and innate immunity. Immunol Today (1998) 0.82
A rapid and simple ELISA for the determination of duplicate monoclonal antibodies during epitope analysis of antigens and its application to the study of C1(-)-INH. J Immunol Methods (1988) 0.82
Immunohistological differential diagnosis of inflammatory colonic diseases. Histopathology (1984) 0.81
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. IV. Formation of EAC42 by treatment of C2 with trypsin in the presence of EAC4. J Immunol (1972) 0.81
Antibody-independent activation of C1, the first component of complement. Ann Immunol (Paris) (1982) 0.81
Molecular basis of a new type of C1q-deficiency associated with a non-functional low molecular weight (LMW) C1q: parallels and differences to other known genetic C1q-defects. Immunopharmacology (1997) 0.81
A case of selective Clq deficiency. Turk J Pediatr (1979) 0.81
Antibodies to Acholeplasma laidlawii membrane lipids in normal guinea pig serum. Infect Immun (1977) 0.81
Monoclonal anti-mouse macrophage antibodies recognize the globular portions of C1q, a subcomponent of the first component of complement. J Immunol (1984) 0.81
Evidence that C1q, a subcomponent of the first component of complement, is an Fc receptor of peritoneal and alveolar macrophages. Immunobiology (1980) 0.81
Studies on the interaction of C1q, a subcomponent of the first component of complement, with porins from Salmonella minnesota incorporated into artificial membranes. FEBS Lett (1990) 0.81
Enzymatic alteration of C1q, the collagen-like subcomponent of the first component of complement, leads to cross-reactivity with type II collagen. FEBS Lett (1988) 0.81
Multiple identification of a particular type of hereditary C1q deficiency in the Turkish population: review of the cases and additional genetic and functional analysis. Hum Genet (1997) 0.81
Complement components (C1, C2, C3, C4) in bronchial secretions after intranasal infection of guinea pigs with Mycoplasma pneumoniae: dissociation of unspecific and specific defense mechanisms. Infect Immun (1979) 0.80
A novel way of relating the structure of Cl1 to the hemolytic activity of the first component of complement. Mol Immunol (1980) 0.80
Detection of C1q-bearing immune complexes by a monoclonal anti-C1q ELISA system. J Immunol Methods (1987) 0.80
Differences in attachment and phagocytosis of Salmonella minnesota strains (S form, Re mutant) by mouse peritoneal macrophages: participation of endogenous C1q and bacterial surface components (LPS, porins). Curr Top Microbiol Immunol (1985) 0.80
The acquired C1-INH deficiencies with autoantibodies (AAE type II). Behring Inst Mitt (1989) 0.80
Common epitopes in Clq and collagen type II. Mol Immunol (1989) 0.80
Interaction of fluid phase C1/C1q and macrophage membrane-associated C1q with gram-negative bacteria. Behring Inst Mitt (1989) 0.80
Effect of EDTA and citrate on the functional activity of the first component of complement, C1, and the C1q subcomponent. Immunobiology (1985) 0.79
Patients with CLL and hypocomplementaemia have an impaired serum bactericidal activity against the Salmonella minnesota Re mutant. Complement (1988) 0.79
Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q. J Immunol (1984) 0.79
The collagen-like component of the complement system, C1q, is recognized by 7 S autoantibodies and is functionally impaired in synovial fluids of patients with rheumatoid arthritis. Immunology (1996) 0.79
Molecular, genetic and epidemiologic studies on selective complete C1q deficiency in Turkey. Immunobiology (2000) 0.79
H2-Mbeta 1 and H2-Mbeta 2 heterodimers equally promote clip removal in I-A(q) molecules from autoimmune-prone DBA/1 mice. J Biol Chem (2001) 0.79
Enzyme-linked immunosorbent assay for C1q in human serum by use of monoclonal antibodies. J Immunol Methods (1984) 0.79